Thomas F. Ryan, Jr. Sells 1,763 Shares of Repligen Co. (RGEN) Stock

Repligen Co. (NASDAQ:RGEN) Director Thomas F. Ryan, Jr. sold 1,763 shares of the company’s stock in a transaction on Monday, November 5th. The shares were sold at an average price of $65.75, for a total value of $115,917.25. Following the sale, the director now owns 3,225 shares of the company’s stock, valued at $212,043.75. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Shares of RGEN opened at $67.98 on Thursday. Repligen Co. has a 12-month low of $29.56 and a 12-month high of $70.50. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of 98.52, a PEG ratio of 5.33 and a beta of 0.74.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, November 1st. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. Repligen had a return on equity of 5.39% and a net margin of 12.61%. The business had revenue of $49.53 million during the quarter, compared to analysts’ expectations of $46.69 million. During the same quarter in the prior year, the firm earned $0.15 EPS. The business’s revenue for the quarter was up 35.4% compared to the same quarter last year. Equities analysts forecast that Repligen Co. will post 0.73 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. Smith Asset Management Group LP increased its holdings in Repligen by 1,511.8% in the 2nd quarter. Smith Asset Management Group LP now owns 4,658 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 4,369 shares in the last quarter. Brown Advisory Inc. increased its holdings in Repligen by 24.0% in the 2nd quarter. Brown Advisory Inc. now owns 8,640 shares of the biotechnology company’s stock worth $406,000 after purchasing an additional 1,673 shares in the last quarter. Granahan Investment Management Inc. MA increased its holdings in Repligen by 12.1% in the 2nd quarter. Granahan Investment Management Inc. MA now owns 178,159 shares of the biotechnology company’s stock worth $8,381,000 after purchasing an additional 19,230 shares in the last quarter. BlackRock Inc. increased its holdings in Repligen by 9.1% in the 2nd quarter. BlackRock Inc. now owns 5,851,161 shares of the biotechnology company’s stock worth $275,239,000 after purchasing an additional 485,777 shares in the last quarter. Finally, Aperio Group LLC increased its holdings in Repligen by 18.6% in the 2nd quarter. Aperio Group LLC now owns 42,196 shares of the biotechnology company’s stock worth $1,985,000 after purchasing an additional 6,613 shares in the last quarter. 93.08% of the stock is owned by institutional investors and hedge funds.

RGEN has been the subject of a number of recent analyst reports. William Blair reiterated an “outperform” rating on shares of Repligen in a research report on Friday, November 2nd. BidaskClub cut Repligen from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 31st. Zacks Investment Research cut Repligen from a “buy” rating to a “hold” rating in a report on Wednesday. ValuEngine raised Repligen from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 23rd. Finally, Citigroup boosted their price target on Repligen from $45.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, July 20th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $59.33.

WARNING: “Thomas F. Ryan, Jr. Sells 1,763 Shares of Repligen Co. (RGEN) Stock” was first reported by WKRB News and is the sole property of of WKRB News. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.wkrb13.com/2018/11/08/thomas-f-ryan-jr-sells-1763-shares-of-repligen-co-rgen-stock.html.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: Why do companies issue stock splits?

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply